文献速递白血病MDS 与骨髓增殖性肿瘤

外周血DNA甲基化特征作为幼年型粒单核细胞白血病阿扎胞苷治疗期间药效动力学和预测性生物标志物的评估:EWOG-MESRAT研究结果

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.
PubMed 文献 · Br J Haematol · 2025-07-31

EWOG-MESRAT研究纳入11例新诊断的幼年型粒单核细胞白血病(JMML)患者,在阿扎胞苷治疗期间采用EPIC芯片检测外周血和骨髓DNA甲基化模式及驱动突变的变异等位基因频率(VAF)。结果显示阿扎胞苷的药效动力学活性可在外周血和骨髓中有效监测,DNA甲基化亚组分类与三个周期后的临床反应相关,且在外周血与骨髓间保持一致;但VAF变化或DNA甲基化模式变化与治疗结局均不相关。

要点

  • 阿扎胞苷的药效动力学活性可在外周血和骨髓中有效监测。
  • DNA甲基化亚组分类与三个周期阿扎胞苷后的临床反应相关,且外周血与骨髓间一致。
  • VAF变化或DNA甲基化模式变化与11例患者的治疗结局均不相关。

核心结论

  • 本研究支持从外周血样本进行DNA甲基化亚组分类用于预测JMML患者单药阿扎胞苷的治疗反应。

研究设计与样本

  • EWOG-MESRAT(欧洲工作组-甲基化特征与阿扎胞苷治疗反应;DRKS00007185)是一项研究者发起的试验,研究11例新诊断JMML患者在阿扎胞苷治疗期间外周血和骨髓的EPIC芯片DNA甲基化模式及基于二代测序(NGS)的驱动突变VAF。

主要发现

  • 阿扎胞苷的药效动力学活性可在外周血和骨髓中有效监测。
  • DNA甲基化亚组分类与三个周期阿扎胞苷后的临床反应相关,且在所有患者中外周血与骨髓间保持一致。
  • 在11例研究患者中,治疗过程中VAF变化和DNA甲基化模式变化均与治疗结局不相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

EWOG-MESRAT (European Working Group-Methylation Signatures and Response to Azacitidine Therapy; DRKS00007185) is an investigator-initiated trial that studied EPIC array-based DNA methylation patterns and next generation sequencing (NGS)-based variant allele frequencies (VAFs) of driver mutations in peripheral blood (PB) and bone marrow (BM) of 11 patients with newly diagnosed juvenile myelomonocytic leukaemia (JMML) during therapy with azacitidine. We demonstrate that the pharmacodynamic activity of azacitidine can efficiently be monitored in PB and BM. DNA methylation subgroup classification was linked to clinical response after three cycles of azacitidine and found to be conserved between PB and BM in all patients. In contrast, neither changes in VAFs nor changes in DNA methylation patterns during the course of therapy correlated with therapy outcome among the 11 study patients. This work thus supports the value of DNA methylation subgroup classification from PB samples for response prediction of single-agent azacitidine in patients with JMML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Schönung M, Rathmann S, Ramamoorthy S, et al. Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study. Br J Haematol. 2025. PMID: 40740143. doi:10.1111/bjh.70046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。